Wilson Sonsini Goodrich & Rosati advised IonQ on the offering, and Paul, Weiss, Rifkind, Wharton & Garrison advised the sales agents. IonQ, Inc. (NYSE: IONQ), a...
You must be a Standard 1 Year member to access this content.
IonQ was advised by Wilson Sonsini Goodrich & Rosati, Homburger AG and ArentFox Schiff on the deal. IonQ (NYSE: IONQ), a leader in the quantum computing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cyrano Therapeutics on the transaction. Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised GI Windows Surgical on the transaction. Massachusetts-based GI Windows Surgical, a clinical-stage medical device company dedicated to developing the first...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised IonQ on the transaction. IonQ (NYSE: IONQ), a leader in quantum computing, announced that it has reached a definitive agreement...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
You must be a Standard 1 Year member to access this content.
